Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.

durvalumab
cancer
metastatic head and neck squamous cell carcinoma
carcinoma
recurrent head and neck carcinoma
  • 17 views
  • 15 Mar, 2021
  • 1 location
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: Durvalumab Tremelimumab Radiation Therapy

hepatitis
durvalumab
cancer
carcinoma
gemcitabine
  • 23 views
  • 02 May, 2021
  • 1 location
Evaluating Immune Therapy Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

The purpose of this study is to test the safety and effectiveness of durvalumab with tremelimumab in patients with relapsed or refractory germ cell tumors.

mg++
progressive disease
beta-human chorionic gonadotropin
tumor markers
neutrophil count
  • 26 views
  • 26 Jan, 2021
  • 7 locations
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Well-differentiated gastroenteropancreatic and lung neuroendocrine tumors are generally malignancies with a prolonged natural history. However, clinical behavior is heterogeneous and when tumor progression is observed, treatment options are limited. The most used therapy for neuroendocrine tumors management are somatostatin analogs. However, even the use in lung carcinoids is quite usual, …

gilbert's syndrome
progressive disease
cancer
carcinoma
neutrophil count
  • 31 views
  • 05 Aug, 2021
  • 28 locations
Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

The addition of durvalumab to total neoadjuvant therapy (TNT) in locally advanced rectal cancer may improve the pathological complete response rate. The induction platinum-based chemotherapy may increase the neoantigen formation together with the chemoradiotherapy period. Starting durvalumab during the first chemotherapy session and continuing during the 6-week period of chemoradiotherapy …

rectal surgery
durvalumab
oxaliplatin
chemoradiotherapy
carcinoma
  • 37 views
  • 28 Jun, 2021
  • 12 locations
AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer

Samsung Medical Centre, Seoul, Korea. Additional 0~5 Korea Lung Cancer Consortium (KLCC) centres in Korea Up to 40 subjects will be enrolled in two-stages (first stage: 19 evaluable subjects and second stage: 17 evaluable subjects and additional 4 subjects considering the drop out rate) If the study is conducted as …

metastasis
serum pregnancy test
hysterectomy
liver metastasis
neutrophil count
  • 0 views
  • 05 Sep, 2021
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

As in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive metastatic disease. Survival of patients with three or fewer metastases was superior compared with patients with more than three lesions. …

metastasis
durvalumab
cancer
bone scan
neutrophil count
  • 16 views
  • 24 Sep, 2021
  • 15 locations
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based standard-combination chemotherapy but eligible for at-least mono-chemotherapy with gemcitabine or vinorelbine.

stage iv non-small cell lung cancer
durvalumab
gemcitabine
neutrophil count
cancer chemotherapy
  • 107 views
  • 29 Jan, 2021
  • 41 locations
Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer

This is an interventional study, to assess feasibility and safety of durvalumab (MEDI4736) in neo-adjuvant setting in patients with resectable NSCLC. Additional analyses of potential imaging

durvalumab
cancer treatment
carcinoma
neutrophil count
cancer chemotherapy
  • 0 views
  • 24 Jan, 2021
  • 1 location
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

This phase III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells …

  • 0 views
  • 26 Sep, 2021
  • 72 locations